Targeting cardiomyocyte GBP5 mitigates cardiac inflammatory injury
Clicks: 2
ID: 323285
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #235 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Cardiac inflammation is a serious adverse effect of contemporary cancer therapies, including immune checkpoint inhibitors (ICIs), anthracyclines, and thoracic irradiation. Although distinct molecular mechanisms contribute to therapy-related cardiotoxicity, shared signaling nodes remain insufficiently characterized. We recently identified guanylate-binding protein 5 (GBP5), a key regulator of NLRP3 inflammasome assembly, as a potential mediator of treatment-induced myocardial inflammation. To define the cardiomyocyte-specific function of GBP5, we generated an inducible, cardiomyocyte-specific knock-in mouse model expressing a truncated, dysfunctional GBP5 variant (GBP5-cKI) lacking the C-terminal domain required for membrane localization and inflammasome assembly. GBP5-cKI and wild-type (WT) mice were subjected to: (i) combined anti–PD-1/anti–CTLA-4 therapy ± IFNγ to model ICI-associated myocarditis; or (ii) doxorubicin administration (3 mg/kg i.p. every 2 days for 8 doses) to induce anthracycline cardiotoxicity; or (iii) 16 Gy thoracic photon irradiation to study radiation-induced cardiac injury. Cardiac function, inflammatory responses, and structural remodeling were assessed by echocardiography, histological analysis, and quantitative PCR. GBP5 expression was markedly increased in all preclinical models of therapy-induced cardiac injury. In contrast to WT controls, cardiomyocyte-specific inactivation of GBP5 significantly attenuated myocardial inflammation, cardiac inflammasome activation (Caspase-1, IL-1β), and pathological remodeling across all oncological treatments. Importantly, GBP5-cKI mice exhibited preserved left ventricular function and improved survival compared with WT controls. These findings identify cardiomyocyte GBP5 as a central regulator of inflammasome-driven myocardial injury in response to cancer therapies. Targeted inactivation of cardiac GBP5 may therefore represent a novel therapeutic strategy to prevent immune-, chemotherapy-, and radiation-induced cardiotoxicity.
| Reference Key |
openalex_W7172308180
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | J Brauer, M Tumani, D Finke, M B Heckmann, M Moustafa, A Abdollahi, N Frey, L H Lehmann |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.029
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.